Analyst Places a Long-Shot Bet on Pluristem (PSTI) Stock
Applied DNA Sciences Tackles COVID-19 on Three Fronts; Analyst Says 'Buy'
Cherry Thomas joins Caribou as SVP of clinical development; Artax locks in Joseph Lobacki as CEO
Palatin Stock Could Soar by Over 300% in the Next Year, Says Top Analyst
3 Biotech Stocks Under $4 That Could Surge Over 50%
3 "Strong Buy" Penny Stocks With Triple-Digit Upside
Fate Therapeutics (FATE) Earnings Report Highlights for Q1 2020
3 Biotech Stocks Under $4 With Massive Upside Ahead
3 Biotech Stocks Under $4 With at Least 50% Upside Potential
A 23,000% Profit in 30 Years
Moderna’s COVID-19 Vaccine Candidate Progressing at 'Warp Speed,' Says Top Analyst
Biotech’s Golden Moment
FDA grants emergency approval to simpler ventilator design
Stocks Amid COVID-19 Outbreak: Winners So Far in the Health Industry
Covid-19 roundup: Gilead selects 5 generic manufacturing partners for remdesivir; CanSino outlines PhI/II study in Canada
The new CEO at troubled AMAG begins his battle against an array of threats by axing staff and slashing costs
FDA issues two guidances to accelerate Covid-19 treatments
Pfizer Plans To Test Covid-19 Vaccine On Thousands Of Patients By September- Report
Gilead Signs Remdesivir Licensing Agreements With Five Drugmakers
CEO Albert Bourla On Pfizer’s Involvement With Covid-19
Moderna CEO Stephane Bancel & Regeneron CEO Leonard Schleifer on a Coronavirus vaccine
Bristol Myers Squibb CEO Giovanni Caforio On COVID-19 Vaccines
Why MyoKardia (MYOK) Stock Could Rise Another 30%
Moderna’s Covid-19 Vaccine Candidate Gets FDA Fast Track Status
3 Biotech Stocks Under $3 With 200%-Plus Upside Potential
With money flowing, Pliant Therapeutics heads to public well
Novavax Spikes 31% on $384 Million Cash Injection for Vaccine Production
GW Pharma Pops 9% After-Hours As Epidiolex Smokes Expectations
Solid Biosciences: Keep Your Eyes On The Prize Says Top Analyst
Seres Therapeutics Reports Weak Earnings, But Significant Upside Lies Ahead